Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.34 |
| ▸ | SORD | Q00796 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1713568 | 0.83 | KDM4E (0.38) | KDM4EGPR119RXFP1SORD | |
| SCHEMBL20012694 | 0.81 | KDM4E (0.37) | KDM4EPTPN11GPR119RXFP1 | |
| SCHEMBL13035353 | 0.80 | KDM4E (0.39) | KDM4ECHRM2CHRM4GPR119RXFP1 | |
| Hydrochloric Acid SCHEMBL19991677 | 0.80 | KDM4E (0.36) | KDM4EPTPN11GPR119 | |
| SCHEMBL1022931 | 0.80 | KDM4E (0.39) | KDM4EPTPN11GPR119RXFP1SORD | |
| SCHEMBL12988802 | 0.76 | KDM4E (0.37) | KDM4ECHRM2CHRM4GPR119RXFP1 | |
| SCHEMBL20009044 | 0.76 | KDM4E (0.37) | KDM4EGPR119RXFP1 | |
| SCHEMBL14467584 | 0.76 | KDM4E (0.40) | KDM4ECHRM4GPR119RXFP1SORD | |
| SCHEMBL5147866 | 0.76 | KDM4E (0.37) | KDM4EPTPN11CHRM4GPR119RXFP1 | |
| SCHEMBL4130328 | 0.73 | CHRM4 (0.47) | KDM4EHRH3CHRM2CHRM4GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | SMARCC1, SMARCC2, SMARCA4 | KDM4E 1623/4885PTPN11 3771/4885HRH3 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.